Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo : delivery vector and immune responses are the key to success

Tuan Nguyen; Ignacio Anegon

doi:10.15252/emmm.201606325

Journal articles

Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo : delivery vector and immune responses are the key to success

Tuan Nguyen ^{1, 2, 3} Ignacio Anegon ^{1, 2, 3, *}

* Corresponding author

1 U1064 Inserm - CRTI - Centre de Recherche en Transplantation et Immunologie

2 ITUN - Institut de transplantation urologie-néphrologie

3 Faculté de Médecine - Université de Nantes

Abstract : Comment on CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. [EMBO Mol Med. 2016]

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Human health and pathology

Complete list of metadata

Cited literature [15 references] Display Hide Download

https://www.hal.inserm.fr/inserm-02150381
Contributor : Sylvie Le Bihan Connect in order to contact the contributor
Submitted on : Friday, June 7, 2019 - 11:30:53 AM
Last modification on : Tuesday, December 8, 2020 - 9:37:39 AM

Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo : delivery vector and immune responses are the key to success

File

Identifiers

Collections

Citation

Export

Metrics

111

198

Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo : delivery vector and immune responses are the key to success

File

Identifiers

Collections

Citation

Export

Share

Metrics

111

198